Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Firefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
OpenA filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenSEC filings, financial facts, source resources, and Goglides workspace context for Datavault AI Inc..
OpenA filing-backed DVLT update explaining Vivasor's Form 3 initial position, Form 4 20M-share sale, Schedule 13G remaining stake, and the proof gate investors should monitor.
OpenDatavault AI's $2.0B structured financing term sheet could give the company a collateral base and global tokenization mandate, but the deal is non-binding, potentially dilutive, and loaded with proof gates.
OpenA beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenA filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenA product-level DVLT diligence addendum that maps VerifyU, ADIO, Datavault, IDE, RWA, and NILX against audited revenue proof, cash conversion, and customer validation.
OpenDatavault AI's Perpetuals.com agreement gives its RWA tokenization story a needed liquidity layer, but the investment case still depends on listings, trading volume, fee recognition, and cash collection.
OpenA source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenA beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenA filing-led diligence review of Datavault AI, focused on revenue quality, cash conversion, dilution, tokenization claims, GPU deployment proof, and validation gates.
OpenA Coverage Bootstrap Datavault AI company evaluation covering data monetization, credentialing, ADIO, RWA tokenization, exchange infrastructure, customer concentration, related-party revenue, dilution, and cash-conversion proof.
OpenA highly bullish but source-gated Datavault AI analysis framing DVLT as a speculative public option on AI data ownership, tokenization, SanQtum edge infrastructure, CyberCatch optionality, and contract-to-cash proof gates.
OpenDatavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenAEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAkso Health Group is pitching an internet-healthcare pivot, but the latest filings show low-margin marketing-promotion revenue, nil interim medical-device revenue, a major impairment and a sharp cash shift into internet-hospital advances.
OpenAdagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
Open